ArticleThe Kobe journal of medical sciences2026
Prognostic Effect of TTF-1 Expression and Histopathology in the Patients with Advanced Lung Adenocarcinoma Treated with Immunochemotherapy.
Article in The Kobe journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe International Association for the Study of Lung Cancer (IASLC) proposed a grading system based on predominant histologic subtypes and reflecting prognosis. We previously reported that thyroid transcription factor-1 (TTF-1) expression levels and tumor cell proportion are useful predictors of immunochemotherapy for lung adenocarcinoma. Building upon our previous findings that TTF-1 negativity was associated with poorer outcomes in patients receiving immunochemotherapy, this study further investigated the relationship between TTF-1 expression and IASLC histologic subtypes, and analyzed progression-free survival (PFS) according to TTF-1 expression within each histologic subtype. MATERIALS AND
methodsWe used the same multicenter retrospective dataset as in our previous study, which was conducted between January 2019 and May 2023. TTF-1 was considered positive as a predictive factor of immunochemotherapy when staining showed high TTF-1 expression. The association between TTF-1 expression, histologic subtype, and mucus-producing components was evaluated.
resultsAmong 95 patients, the positivity rate for TTF-1 was 61.1%. The negative rate of TTF-1 in mucus-producing adenocarcinomas was significantly higher than that in non-mucus-producing adenocarcinomas (18/29 [62.1%] vs. 18/63 [28.6%]; p < 0.01). As per the analysis of IASLC grade 3, the median PFS of TTF-1 negative patients was significantly worse than that of positive patients (6.0 vs. 7.6 months, p = 0.035). Among patients with solid predominant patterns, the median PFS was significantly worse in the patients with TTF-1 negative than positive (5.2 vs. 8.5 months, p = 0.014).
conclusionThis study shows that the combination of histopathology and TTF-1 expression is a predictive factor in patients treated with combined immunochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.